Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

D Meulendijks, W Jacob, EE Voest, M Mau-Sorensen, M Martinez-Garcia, A Taus, T Fleitas, A Cervantes, Martijn Lolkema, M H G Langenberg, Maja de Jonge, Stefan Sleijfer, JY Han, A Calles, E Felip, SW Kim, JHM Schellens, S Wilson, M Thomas, M CeppiG Meneses-Lorente, I James, S Vega-Harring, R Dua, M Nguyen, L Steiner, C Adessi, F Michielin, B Bossenmaier, M Weisser, U N Lassen

Research output: Contribution to journalArticleAcademicpeer-review

28 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)5406-5415
Number of pages10
JournalClinical Cancer Research
Issue number18
Publication statusPublished - 2017

Research programs

  • EMC MM-03-86-08

Cite this